公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2020 | The AFSUMB consensus statements and recommendations for the clinical practice of contrast-enhanced ultrasound using sonazoid | Lee J.Y.; Minami Y.; Choi B.I.; Lee W.J.; Chou Y.-H.; Jeong W.K.; Park M.-S.; Kudo N.; Lee M.W.; Kamata K.; Iijima H.; Kim S.Y.; Numata K.; Sugimoto K.; Maruyama H.; Sumino Y.; Ogawa C.; Kitano M.; Joo I.; Arita J.; JA-DER LIANG ; Lin H.-M.; Nolsoe C.; Gilja O.H.; Kudo M. | Journal of Medical Ultrasound | 22 | 12 | |
2020 | The afsumb consensus statements and recommendations for the clinical practice of contrast-enhanced ultrasound using sonazoid | Lee J.Y.; Minami Y.; Choi B.I.; Lee W.J.; Chou Y.-H.; Jeong W.K.; Park M.-S.; Kudo N.; Lee M.W.; Kamata K.; Iijima H.; Kim S.Y.; Numata K.; Sugimoto K.; Maruyama H.; Sumino Y.; Ogawa C.; Kitano M.; Joo I.; Arita J.; JA-DER LIANG ; Lin H.-M.; Nolsoe C.; Gilja O.H.; Kudo M. | Ultrasonography | 47 | 42 | |
2011 | Asian consensus workshop report: Expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia | Han K.-H.; Kudo M.; Ye S.-L.; Choi J.Y.; Poon R.T.-P.; Seong J.; Park J.-W.; Ichida T.; Chung J.W.; Chow P.; ANN-LII CHENG | Oncology | 98 | 98 | |
2021 | The Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB) Guidelines for Contrast-Enhanced Endoscopic Ultrasound | Kitano M.; Yamashita Y.; Kamata K.; Ang T.L.; Imazu H.; Ohno E.; Hirooka Y.; Fusaroli P.; Seo D.-W.; Napoléon B.; Teoh A.Y.B.; Kim T.H.; Dietrich C.F.; HSIU-PO WANG ; Kudo M.; Working group for the International Consensus Guidelines for Contrast-Enhanced Harmonic Endoscopic Ultrasound | Ultrasound in Medicine and Biology | 20 | 15 | |
2010 | Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma | Omata M.; Lesmana L.A.; Tateishi R.; PEI-JER CHEN ; Lin S.-M.; Yoshida H.; Kudo M.; Lee J.M.; Choi B.I.; Poon R.T.P.; Shiina S.; ANN-LII CHENG ; Jia J.-D.; Obi S.; Han K.H.; Jafri W.; Chow P.; Lim S.G.; Chawla Y.K.; Budihusodo U.; Gani R.A.; Lesmana C.R.; Putranto T.A.; Liaw Y.F.; Sarin S.K. | Hepatology International | 881 | 860 | |
2017 | Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update | Omata M.; ANN-LII CHENG ; Kokudo N.; Kudo M.; Lee J.M.; Jia J.; Tateishi R.; Han K.-H.; Chawla Y.K.; Shiina S.; Jafri W.; Payawal D.A.; Ohki T.; Ogasawara S.; PEI-JER CHEN ; Lesmana C.R.A.; Lesmana L.A.; Gani R.A.; Obi S.; Dokmeci A.K.; Sarin S.K. | Hepatology International | 1451 | 1303 | |
2020 | Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma | Finn R.S.; Qin S.; Ikeda M.; Galle P.R.; Ducreux M.; Kim T.-Y.; Kudo M.; Breder V.; Merle P.; Kaseb A.O.; Li D.; Verret W.; Xu D.-Z.; Hernandez S.; Liu J.; Huang C.; Mulla S.; Wang Y.; Lim H.Y.; Zhu A.X.; ANN-LII CHENG ; IMbrave150 Investigators | New England Journal of Medicine | 3470 | 3126 | |
2013 | Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study | Johnson P.J.; Qin S.; Park J.-W.; Poon R.T.P.; Raoul J.-L.; Philip P.A.; CHIH-HUNG HSU ; Hu T.-H.; Heo J.; Xu J.; Lu L.; Chao Y.; Boucher E.; Han K.-H.; Paik S.-W.; Robles-Aviña J.; Kudo M.; Yan L.; Sobhonslidsuk A.; Komov D.; Decaens T.; Tak W.-Y.; Jeng L.-B.; Liu D.; Ezzeddine R.; Walters I.; ANN-LII CHENG | Journal of Clinical Oncology | 618 | 595 | |
2020 | Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma | ANN-LII CHENG ; CHIUN HSU ; Chan S.L.; Choo S.-P.; Kudo M. | Journal of Hepatology | 297 | 267 | |
2020 | A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements | Kudo M.; Han K.-H.; Ye S.-L.; Zhou J.; Huang Y.-H.; Lin S.-M.; Wang C.-K.; Ikeda M.; Chan S.L.; Choo S.P.; Miyayama S.; ANN-LII CHENG | Liver Cancer | 150 | 146 | |
2013 | Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC) | Park J.-W.; Amarapurkar D.; Chao Y.; PEI-JER CHEN ; Geschwind J.-F.H.; Goh K.L.; Han K.-H.; Kudo M.; Lee H.C.; Lee R.-C.; Lesmana L.A.; Lim H.Y.; Paik S.W.; Poon R.T.; Tan C.-K.; Tanwandee T.; Teng G.; ANN-LII CHENG | Liver International | 69 | 60 | |
2019 | Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma (British Journal of Cancer, (2019), 121, 3, (218-221), 10.1038/s41416-019-0506-6) | Evans T.R.J.; Kudo M.; Finn R.S.; Han K.-H.; ANN-LII CHENG ; Ikeda M.; Kraljevic S.; Ren M.; Dutcus C.E.; Piscaglia F.; Sung M.W. | British Journal of Cancer | 2 | 2 | |
2019 | Corrigendum to “Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis” [J Hepatol 71 (2019) 543–552](S0168827819303009)(10.1016/j.jhep.2019.05.014) | Yau T.; CHIUN HSU ; Kim T.-Y.; Choo S.-P.; Kang Y.-K.; Hou M.-M.; Numata K.; Yeo W.; Chopra A.; Ikeda M.; Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Dela Cruz C.; Kudo M. | Journal of Hepatology | 1 | 9 | |
2020 | Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma | Alsina A.; Kudo M.; Vogel A.; ANN-LII CHENG ; Tak W.Y.; Ryoo B.-Y.; Evans T.R.J.; L?pez L?pez C.; Daniele B.; Misir S.; Ren M.; Izumi N.; Qin S.; Finn R.S. | Liver Cancer | 54 | 48 | |
2020 | Efficacy and Safety of Nivolumab plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040 Randomized Clinical Trial | Yau T.; Kang Y.-K.; Kim T.-Y.; El-Khoueiry A.B.; Santoro A.; Sangro B.; Melero I.; Kudo M.; Hou M.-M.; Matilla A.; Tovoli F.; Knox J.J.; Ruth He A.; El-Rayes B.F.; Acosta-Rivera M.; Lim H.-Y.; Neely J.; Shen Y.; Wisniewski T.; Anderson J.; CHIUN HSU | JAMA Oncology | 697 | 646 | |
2020 | Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies | Yen C.-J.; Kudo M.; Lim H.-Y.; CHIH-HUNG HSU ; Vogel A.; Brandi G.; Cheng R.; Nitu I.S.; Abada P.; Hsu Y.; Zhu A.X.; Kang Y.-K. | Liver Cancer | 12 | 10 | |
2015 | Global patterns of hepatocellular carcinoma management from diagnosis to death: The BRIDGE Study | Park J.-W.; Chen M.; Colombo M.; Roberts L.R.; Schwartz M.; PEI-JER CHEN ; Kudo M.; Johnson P.; Wagner S.; Orsini L.S.; Sherman M. | Liver International | 779 | 694 | |
2021 | Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYnote-240 | Ryoo B.-Y.; Merle P.; Kulkarni A.S.; ANN-LII CHENG ; Bouattour M.; Lim H.Y.; Breder V.; Edeline J.; Chao Y.; Ogasawara S.; Yau T.; Garrido M.; Chan S.L.; Daniele B.; Norquist J.M.; Chen E.; Siegel A.B.; Zhu A.X.; Finn R.S.; Kudo M. | Cancer | 13 | 17 | |
2020 | IMbrave 050: A Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation | Hack S.P.; Spahn J.; Chen M.; ANN-LII CHENG ; Kaseb A.; Kudo M.; Lee H.C.; Yopp A.; Chow P.; Qin S. | Future Oncology | 120 | 105 | |
2018 | Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial | Kudo M.; Finn R.S.; Qin S.; Han K.-H.; Ikeda K.; Piscaglia F.; Baron A.; Park J.-W.; Han G.; Jassem J.; Blanc J.F.; Vogel A.; Komov D.; Evans T.R.J.; Lopez C.; Dutcus C.; Guo M.; Saito K.; Kraljevic S.; Tamai T.; Ren M.; ANN-LII CHENG | The Lancet | 3386 | 3008 |